title: Celecoxib pathways:  pharmacokinetics and pharmacodynamics.
authors.affiliation: Department of Genetics, Stanford University, Stanford, California, USA.
authors.forename: Li
authors.initials: L
authors.lastname: Gong
authors.forename: Caroline F
authors.initials: CF
authors.lastname: Thorn
authors.forename: Monica M
authors.initials: MM
authors.lastname: Bertagnolli
authors.forename: Tilo
authors.initials: T
authors.lastname: Grosser
authors.forename: Russ B
authors.initials: RB
authors.lastname: Altman
authors.forename: Teri E
authors.initials: TE
authors.lastname: Klein
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D054316:Biomarkers, Pharmacological; D018376:Cardiovascular Abnormalities / Q000139:chemically induced; D000068579:Celecoxib; D051545:Cyclooxygenase 1 / Q000235:genetics / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D065729:Cytochrome P-450 CYP2C9; D056726:Genetic Association Studies; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D053858:Metabolic Networks and Pathways / Q000235:genetics; D011720:Pyrazoles / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D054316:Biomarkers, Pharmacological; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D000068579:Celecoxib